We are live on ! Find out more

State Street SPDR S&P Biotech ETF

XBI

Market cap $11.7B

164.38 USD

-0.99

0.6%

At close Updated Sep 3, 4:00 PM EDT

Pre-market

After hours

164.26

-0.12

0.07%

1 day

-0.6%

5 days

-1.4%

1 month

11.59%

3 months

26.61%

6 months

33.1%

Year to date

35.27%

1 year

75.53%

5 years

22.5%

10 years

166.29%

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 66.7%

Neutral 27.8%

Negative 5.6%

Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs

The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc's (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive investor interest in genomics, immunotherapy and precision medicine ETFs.

Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs

Zacks Investment Research

Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough

Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.

Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough

XBI Forecast: $174.79 Tests Biotech ETF Breakout Strength

XBI approaches its 2021 high at $174.79 after a bullish flag breakout, setting up a key test between further gains and a potential consolidation.

XBI Forecast: $174.79 Tests Biotech ETF Breakout Strength

Zacks Investment Research

Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)?

Launched on January 31, 2006, the State Street SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.

Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)?

XBI: Biotech's Breakthrough Moment Happend This Week (Upgrade)

State Street SPDR S&P Biotech ETF (XBI) is upgraded to buy as bullish momentum and reasonable valuation converge amid sector-wide optimism. XBI has surged 34% since March, outperforming XLV and SPY, fueled by M&A activity and positive clinical trial catalysts. Despite high volatility and small-cap risk, XBI's under-20x earnings multiple and diversified holdings support a constructive outlook.

XBI: Biotech's Breakthrough Moment Happend This Week (Upgrade)

The Motley Fool

IHE vs. XBI: Pharma Stability or Biotech Growth -- Which Healthcare ETF Is the Better Buy?

The iShares U.S. Pharmaceuticals ETF (IHE) offers a higher dividend yield and significantly lower historical volatility than the State Street SPDR S&P Biotech ETF (XBI). XBI has outperformed IHE on a one-year basis, but XBI's growth has come with a much steeper five-year maximum drawdown.

IHE vs. XBI: Pharma Stability or Biotech Growth -- Which Healthcare ETF Is the Better Buy?

The Motley Fool

XBI vs. FBT: Broad Biotech Exposure or Concentrated Bets?

State Street SPDR S&P Biotech ETF carries a lower expense ratio of 0.35% compared to First Trust NYSE Arca Biotechnology Index Fund. FBT maintains a highly concentrated portfolio of only 30 holdings, while XBI spans 155 companies.

XBI vs. FBT: Broad Biotech Exposure or Concentrated Bets?

The Motley Fool

Which Healthcare ETF Is the Better Buy: VanEck's Pharma PPH or State Street's Biotech XBI?

VanEck Pharmaceutical ETF offers a lower-volatility profile and a higher 1.9% dividend yield compared to State Street SPDR S&P Biotech ETF. State Street SPDR S&P Biotech ETF provides broad exposure with 155 holdings, whereas VanEck Pharmaceutical ETF is concentrated in 26 major drugmakers.

Which Healthcare ETF Is the Better Buy: VanEck's Pharma PPH or State Street's Biotech XBI?

Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes

Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO activity are restoring capital flows and investor confidence in biotech equities.

Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes

The Motley Fool

iShares Global Healthcare ETF vs State Street SPDR Biotech ETF. Which Healthcare-Focused Fund Will Bring You Profits in 2026 and Beyond?

iShares Global Healthcare ETF offers a 1.4% dividend yield and lower price volatility than State Street SPDR S&P Biotech ETF. State Street SPDR S&P Biotech ETF focuses on U.S. biotechnology, resulting in a higher 1-year total return of 80.2% but a significantly deeper maximum drawdown.

iShares Global Healthcare ETF vs State Street SPDR Biotech ETF. Which Healthcare-Focused Fund Will Bring You Profits in 2026 and Beyond?

See News Rankings

Price charts implemented using Lightweight Charts™